| 米氮平治疗广泛性焦虑症的临床观察 |
| |
| 引用本文： | 王佩蓉,;陈文松. 米氮平治疗广泛性焦虑症的临床观察[J]. 山东农业大学学报(社会科学版), 2008, 0(1) |
| |
| 作者姓名： | 王佩蓉, 陈文松 |
| |
| 作者单位： | [1]浙江省立同德医院; [2]310012 |
| |
| 摘 要： | 目的探讨米氮平治疗广泛性焦虑症(GAD)的临床疗效及安全性。方法共85例广泛性焦虑症患者入组,米氮平治疗46例,对照观察组39例,共观察8周,使用HAMA判断疗效,并记录不良反应。结果74例完成研究(米氮平41例,对照组33例)。研究终点,米氮平组HAMA减分平均为12.5±5.8,对照组减分平均为7.7±6.5,两组比较差异有统计学意义(t=3.35,P(0.01);米氮平治疗后14天及其后各随访点HAMA减分与观察组比较差异均有统计学意义;米氮平治疗GAD的有效率71%,显著优于观察组(39%)(2χ=7.32,P<0.01);米氮平的主要不良反应为体重增加、食欲增强、嗜睡及头晕。结论米氮平治疗GAD有效,依从性高,不良反应不多见,可作为临床治疗GAD的一种选择。
|
| 关 键 词： | 广泛性焦虑症 米氮平 疗效 安全性 |
Efficacy and safety of mirtazapine in outpatients with generalized anxiety disorder |
| |
| Affiliation: | Wang Peirong; Chen Wensong.Tongde Hospital of Zhejiang Province; Hangzhou 310012; |
| |
| Abstract: | Objective: An open,parallel-group trial was conducted to compare the 8-week efficacy and safety of mirtazapine in outpatients with GAD without associated MDD.Methods: A total of 85 outpatients aged 18 years or older who met CCMD-3 criteria for GAD were assigned to receive either observed(n=39) or mirtazapine(15,or more,as required to control symptoms;n=46) for 8 weeks,and changes from baseline in the Hamilton Rating Scale for Anxiety(HAM-A) total score of two groups and adverse events were compared.Results:... |
| |
| Keywords: | Generalized anxiety disorder Mirtazapine Efficacy Safety |
| 本文献已被 维普 等数据库收录！ |
|
